Enlivex Ltd. ENLV
Enlivex Ltd. (Nasdaq: ENLV) is an immunology/inflammation drug developer. Its lead program, Allocetra, is in Phase 2 for Moderate-to-severe age-related primary knee osteoarthritis. Its next catalyst on record is Allocetra Phase IIb knee OA: Three-month topline data (Q2 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Allocetra Phase IIb knee OA — Three-month topline data (Q2 2027). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Allocetra (intra-articular, Phase IIb) | Age-related primary knee osteoarthritis | biologic-other | Phase 2 |
Recent results and decisions
- Oct 27, 2026n/a Enlivex announces a 1-for-16 reverse share split to become effective October 27, 2026.
Every 16 ordinary shares will automatically be combined into one ordinary share.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 immunology/inflammation companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.